Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

  title={Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology},
  author={Jacques Touchon and Howard Bergman and Roger Alan Bullock and Guenter Rapatz and Jennifer Nagel and Roger M. Lane},
  journal={Current Medical Research and Opinion},
  pages={49 - 59}
ABSTRACT Methods: AD patients were divided by the presence/absence of symptoms suggestive of concomitant Lewy body disease. These were identified by a concomitant diagnosis of dementia with Lewy bodies and/or use of anti-parkinsonian medication at baseline. Baseline characteristics, demographics, changes on efficacy parameters and adverse event (AE) frequencies were calculated for rivastigmine- and donepezil-treated patients. Efficacy parameters were the Severe Impairment Battery (SIB), Mini… 

Comparative Study of Rivastigmine and Donepezil on Cognitive Function in Mild to Moderate Dementia

Treatment with rivastigmine and donepezil increases cognitive function by measurement of MMSE in patients with mild to moderate dementia.

Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia

Rivastigmine did not induce clinically significant exacerbation of motor dysfunction in patients with PDD and posthoc analysis showed that similar improvements in the symptoms of dementia, including the ability to perform activities of daily living, were seen regardless of whether exacerbations of tremor was reported during the study.

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics

  • R. Cacabelos
  • Biology, Medicine
    Neuropsychiatric disease and treatment
  • 2007
Although donepezil represents a non cost-effective treatment, most studies convey that this drug can provide a modest benefit on cognition, behavior, and activities of the daily living in both moderate and severe AD, contributing to slow down disease progression and, to a lesser exetnt, to delay institutionalization.

Donepezil: an update

  • B. Seltzer
  • Biology, Medicine
    Expert opinion on pharmacotherapy
  • 2007
The efficacy of donepezil is limited, and ongoing studies are investigating other agents that may ultimately overtake its present position as the mainstay of anti-AD therapy.

The Potential Role of Donepezil for the Treatment of Dementia w ithLewy Bodies

Clinical benefits and good tolerability have recently been reported in several clinical trials of cholinesterase inhibitors (ChEIs), particularly donepezil, particularlydonepezil.

Distinguishing Lewy body dementias from Alzheimer’s disease

There are currently no definitive radiological or biological markers for LBD, but studies suggest that premorbid differences in cognitive domains and personality traits, differences in clinical presentation, and alterations in autonomic function and sleep may improve diagnosis.

Update on Dementia with Lewy Bodies

Dementia with Lewy bodies (DLB) is the second most common form of dementia after Alzheimer disease (AD). DLB is characterized pathologically by Lewy body and Lewy neuritic pathology, often with

Donepezil for dementia due to Alzheimer's disease.

  • J. BirksR. Harvey
  • Medicine, Psychology
    The Cochrane database of systematic reviews
  • 2018
After 26 weeks of treatment, donepezil compared with placebo was associated with better outcomes for cognitive function measured with the Alzheimer's Disease Assessment Scale-Cognitive, and the effect ofdonepezil on healthcare resource use and costs was assessed.

Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review

A systematic review of the predictors of response to AChEI in neurodegenerative dementias provides a categorization and interpretation of the results, finding high heterogeneity in duration, response definition, drug dosage, and diagnostic criteria.

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

Sex and BuChE genotype seem to differentially influence the type of decline in MCI patients, with more rapid progression of cognitive decline in male Bu cholinesterase-K, and more incident AD and functional decline in female Bu ChE wt/wt.



Rivastigmine for dementia associated with Parkinson's disease.

Rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor; however, the differences between these two groups were moderate and similar to those reported in trials of rivastIGmine for Alzheimer's disease.

Donepezil for behavioural disorders associated with Lewy bodies: a case series

Five of the seven patients diagnosed with DLB were treated with the acetylcholinesterase inhibitor donepezil to determine its effect on treating behavioural disorders, and three showed marked improvement in behaviour, with NPI scores dropping significantly over time.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

Although both drugs performed similarly on cognition and behaviour, rivastigmine may provide greater benefit in activities of daily living and global functioning.

Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms over the first 24 weeks of treatment with rivastigmine, and by 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

Donepezil for Treatment of Dementia With Lewy Bodies: A Case Series of Nine Patients

Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function, and was sometimes associated with worse parkinsonism.

Extrapyramidal signs in patients with probable Alzheimer disease.

In this cohort, the presence or absence of EPSs is related to time to institutionalization, but not to severe cognitive or functional impairment or death, and it appears that a subgroup of patients with AD with EPSs can have a worse outcome.

Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System

Benefits to cognitive function were accompanied by a significant improvement of the other primary outcome measure, the Neuropsychiatric Inventory, three weeks after discontinuation of rivastigmine, most parameters of cognitive performance returned to predrug levels.

Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease.

The presence of EPSs in patients with AD indicates worse prognosis and may be related to underlying LBs, which is a strong predictor of LBs.

Predictors of progression in patients with AD and Lewy bodies

Patients with AD+LB can develop EPS and diurnal hypersomnia earlier and have faster time to institutionalization than those with AD alone, but cognitive and functional decline and physical survival are similar between these two entities.